GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Shandong Sinobioway Biomedicine Co 002581.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

4.14

+1.47%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Shandong Sinobioway Biomedicine Co

Its shares trade on Shenzhen under the ticker 002581.SZ. It has been listed since 20 May 2011. In the fiscal year to 31 December 2025, it reported revenue of CN¥274.8m and a net loss of CN¥116.3m. At that date it held total assets of CN¥2.17bn and shareholders' equity of CN¥1.84bn.

Shandong Sinobioway Biomedicine Co., Ltd. engages in the research and development, manufacture, and sale of chemical raw materials, chemical and pharmaceutical products. The company is headquartered in Shenzhen, Guangdong. The company went IPO on 2011-05-20. The firm is engaged in the business of interferon, nerve growth factor, biopharmaceutical contract research organization (CRO)/pharmaceutical contract development and manufacturing enterprise (CDMO), vaccines and pharmaceutical intermediates. The firm's main products include anferon, encyclopedia, Corona Virus Disease2019 vaccine and others. The firm distributes its products within domestic market.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
20 May 2011
Employees
666

Leadership

Pay as last reported

  • Mr. Jialin YueChairman of the Board, General Manager, since 2022
  • Mr. Juanxiong XuVice Chairman of the Board, Deputy General Manager, since 2022
  • Ms. Ting ZhouChief Financial Officer, Staff Elected Director, since 2024
  • Ms. Xing ChenDeputy General Manager, Director, since 2025
  • Ms. Xiaoru ShiSecretary of the Board, Director, since 2024
  • Mr. Guiyuan HuangDirector
  • Mr. Wenjun LiuDirector, since 2022
  • Ms. Yanhong CaiIndependent Director
  • Mr. Yang XiaIndependent Director
  • Mr. Jun YangIndependent Director
  • Mr. Rongfu ZhangIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Company employs 666 full-time employees
  • Headquartered in Shenzhen, Guangdong
  • Engaged in research and development of pharmaceutical products

Weaknesses

  • No international market presence mentioned
  • Products distributed only within domestic market
  • No information on financial performance or market share

Opportunities

  • Potential growth in biopharmaceutical CRO/CDMO services
  • Expanding market for vaccines including Corona Virus Disease2019 vaccine
  • Growth in demand for pharmaceutical intermediates

Threats

  • Reliance on domestic market only
  • No information on competition or market saturation
  • Untrusted source description may contain inaccuracies

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.